AFP2d
Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10
To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals Fourth Quarter 2024 Earnings Call.” ...
Pharmabiz14d
Vertex Pharmaceuticals’ suzetrigine gets US FDA approval for treatment of adults with moderate-to-severe acute pain
Vertex Pharmaceuticals Incorporated, an American biopharmaceutical company based in Boston, announced that the US Food and Drug Administration (FDA) has approved its Journavx (suzetrigine), an oral, ...
The Boston Globe14d
At $31 a day, is Vertex’s new non-addictive painkiller worth the price?
That’s the opinion of top Vertex Pharmaceuticals executives and several market analysts about the Boston-based company’s painkiller Journavx, which the Food and Drug Administration approved on ...
Forbes14d
Millie Chandarana Aims To Take Unbeaten Nottingham Forest To WNL Title
digital filters) Millie Chandarana of Nottingham Forest in action during the The FA Women's National League game between Hull City Ladies and Nottingham Forest Women at Easy Buy Stadium ...
Reuters14d
Vertex Pharmaceuticals Inc
Wall St ends lower as White House says Trump to implement tariffs February 1, 2025 The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health ...
Indiatimes14d
US FDA approves new painkiller Journavx as alternative to opioids
US Federal officials have approved a new pain pill by Vertex Pharmaceuticals called Journavx ... before it gets to the brain," Vertex's Dr David Altshuler was quoted as saying by news agency ...
Seeking Alpha14d
Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug
Vertex Pharmaceuticals continues to execute its commercialization of three new drugs, JOURNAVX, CASGEVY, and ALYFTREK. Two of which have been approved by the FDA since December. Vertex's valuation ...
Fox Business14d
Vertex Pharmaceuticals' non-opioid pain medication gets FDA approval
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval ... for Drug Evaluation and Research Acting Director Dr. Jacqueline Corrigan-Curay said. "This action and the ...
Investing15d
Vertex Pharmaceuticals' SWOT analysis: cystic fibrosis leader faces pipeline challenges
Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...
Benzinga.com15d
FDA Approves First Non-Opioid Pain Pill, As Medical Marijuana Remains A Proven Alternative For Relief
As with medical marijuana, Vertex Pharmaceuticals' new pain drug is ... pain and provides patients with another treatment option," Dr. Jacqueline Corrigan-Curay, acting director of the FDA's ...
Wall Street Journal15d
Vertex Pharmaceuticals Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Investopedia15d
Vertex Pharmaceuticals Stock Jumps as Non-Opioid Painkiller Gets FDA Approval
JOSEPH PREZIOSO / AFP via Getty Images Vertex Pharmaceuticals' non-opioid painkiller ... of adults with moderate-to-severe acute pain." CEO Dr. Reshma Kewalramani said Journavx was "the first ...